Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK1 | Q96PY6 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 3/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26213160 | 0.90 | HTR1A (0.45) | NEK1HTR7HTR1ADRD2HTR6 | |
| SCHEMBL26213138 | 0.87 | NEK1 (0.44) | NEK1HTR7HTR1ADRD2HTR6 | |
| SCHEMBL30270474 | 0.87 | NEK1 (0.44) | NEK1HTR7HTR1ADRD2HTR6 | |
| SCHEMBL26213188 | 0.84 | HTR1A (0.43) | NEK1HTR7HTR1ADRD2HTR6 | |
| SCHEMBL26213178 | 0.84 | HTR7 (0.47) | NEK1HTR7HTR1ADRD2HTR6 | |
| SCHEMBL26213077 | 0.83 | KDM1A (0.47) | HTR7HTR1ADRD2HTR6KDM4E | |
| SCHEMBL26213059 | 0.83 | KMT2A (0.49) | HTR7HTR1ASIGMAR1KDM1A | |
| SCHEMBL26213157 | 0.82 | HTR1A (0.48) | HTR7HTR1ADRD2HTR6SIGMAR1 | |
| SCHEMBL26213183 | 0.81 | HTR1A (0.43) | NEK1HTR7HTR1ADRD2HTR6 | |
| SCHEMBL26213146 | 0.81 | HTR1A (0.41) | NEK1HTR7HTR1ADRD2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115843271-B | Indole derivatives and their use for the treatment of cancer | 克洛德贝纳尔-里昂第一大学 | 2024-08-13 | — | — | CN | disclosed |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2023-09-07 | — | — | US | disclosed |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2023-09-07 | — | — | US | disclosed |
| CN-115843271-A | Indole derivatives and their use for the treatment of cancer | 克洛德贝纳尔-里昂第一大学 | 2023-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | CSNK2A1, IDO1, CSNK2A3 | NEK1 288/4885HTR7 414/4885HTR1A 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.